V1RG6 Inhibitors
V1RG6 inhibitors are a specific class of chemical compounds designed to target and modulate the activity of the V1RG6 protein, which is part of the larger V-ATPase (vacuolar-type H+-ATPase) complex. The V-ATPase complex is integral to numerous cellular processes, particularly in the regulation of intracellular pH and ion gradients. The V1RG6 protein is a subunit of the V1 domain of this complex, which is essential for the hydrolysis of ATP. This ATP hydrolysis is what powers the proton pumps of the V-ATPase, enabling it to transport protons across membranes and create acidic environments within various cellular compartments such as lysosomes, endosomes, and vacuoles.
The function of V1RG6 inhibitors is centered around their ability to bind specifically to the V1RG6 protein. This binding interaction disrupts the normal operation of the V1 domain of the V-ATPase complex. By inhibiting V1RG6, these compounds interfere with the assembly or activity of the V1 domain, thereby affecting the ATP hydrolysis process and consequently the proton-pumping activity of the V-ATPase. This disruption can have a cascading effect on the cellular pH regulation and various processes that depend on the function of V-ATPase. V1RG6 inhibitors thus play a role in understanding the intricate mechanisms of proton transport and pH homeostasis within cells, providing insights into the functioning and regulation of the V-ATPase complex.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits NF-κB activation, potentially reducing the transcriptional activity of NF-κB on V1R75 expression. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $155.00 | 6 | |
Celastrol has been shown to inhibit gene expression by interfering with transcription factors or signaling cascades. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $127.00 $572.00 $4090.00 $20104.00 | 20 | |
Withaferin A may inhibit V1R75 expression by interfering with transcriptional regulators or signaling cascades. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to intracellular calcium depletion, which may downregulate V1R75 expression. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil inhibits L-type calcium channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R75 expression. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $173.00 $612.00 | 3 | |
Cyclopiazonic acid inhibits SERCA, leading to intracellular calcium depletion, which may downregulate V1R75 expression. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine inhibits L-type calcium channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R75 expression. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin increases intracellular calcium levels by facilitating calcium influx, which may activate calcium-dependent signaling pathways involved in V1R75 expression. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $101.00 $155.00 $389.00 $643.00 | 2 | |
SKF-96365 inhibits store-operated calcium entry (SOCE), potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R75 expression. | ||||||
Gadolinium(III) chloride | 10138-52-0 | sc-224004 sc-224004A | 5 g 25 g | $150.00 $350.00 | 4 | |
Gadolinium chloride inhibits non-selective cation channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R75 expression. | ||||||